Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder
- PMID:26506581
- PMCID: PMC4625086
- DOI: 10.1016/j.jaac.2015.08.013
Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder
Abstract
Objective: Impairments associated with attention-deficit/hyperactivity disorder (ADHD) and noncompliance are prevalent in children with autism spectrum disorder (ASD). However, ADHD response to stimulants is well below rates in typically developing children, with frequent side effects. Group studies of treatments for noncompliance are rare in ASD. We examined individual and combined-effectiveness of atomoxetine (ATX) and parent training (PT) for ADHD symptoms and noncompliance.
Method: In a 3-site, 10-week, double-blind, 2 × 2 trial of ATX and PT, 128 children (ages 5-14 years) with ASD and ADHD symptoms were randomized to ATX, ATX+PT, placebo+PT, or placebo. ATX was adjusted to optimal dose (capped at 1.8 mg/kg/day) over 6 weeks and maintained for 4 additional weeks. Nine PT sessions were provided. Primary outcome measures were the parent-rated DSM ADHD symptoms on the Swanson, Nolan and Pelham (SNAP) scale and Home Situations Questionnaire (HSQ).
Results: On the SNAP, ATX, ATX+PT and placebo+PT were each superior to placebo (effect sizes 0.57-0.98; p values of .0005, .0004, and .025, respectively). For noncompliance, ATX and ATX+PT were superior to placebo (effect sizes 0.47-0.64; p values .03 and .0028, respectively). ATX was associated with decreased appetite but was otherwise well tolerated.
Conclusion: Both ATX and PT resulted in significant improvement on ADHD symptoms, whereas ATX (both alone and combined with PT) was associated with significant decreases on measures of noncompliance. ATX appears to have a better side effects profile than psychostimulants in the population with ASD.
Clinical trial registration information: Atomoxetine, Placebo and Parent Management Training in Autism; http://clinicaltrials.gov/;NCT00844753.
Keywords: ADHD; atomoxetine; autism spectrum disorder; clinical trial; parent training.
Copyright © 2015 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure: Drs. Hyman, Tumuluru, Lecavalier, Pan, Silverman, Rice, Jr., Mruzek, Levato, Smith, and Mss. Corbett-Dick, Buchan-Page, Brown, McAuliffe-Bellin, and Ryan report no biomedical financial interests or potential conflicts of interest.
Figures
Similar articles
- A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.Arnold LE, Ober N, Aman MG, Handen B, Smith T, Pan X, Hyman SL, Hollway J, Lecavalier L, Page K, Rice R Jr.Arnold LE, et al.J Child Adolesc Psychopharmacol. 2018 Jun;28(5):322-330. doi: 10.1089/cap.2017.0134. Epub 2018 Apr 25.J Child Adolesc Psychopharmacol. 2018.PMID:29694241Free PMC article.Clinical Trial.
- Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study.Smith T, Aman MG, Arnold LE, Silverman LB, Lecavalier L, Hollway J, Tumuluru R, Hyman SL, Buchan-Page KA, Hellings J, Rice RR Jr, Brown NV, Pan X, Handen BL.Smith T, et al.J Am Acad Child Adolesc Psychiatry. 2016 Oct;55(10):868-876.e2. doi: 10.1016/j.jaac.2016.06.015. Epub 2016 Aug 2.J Am Acad Child Adolesc Psychiatry. 2016.PMID:27663942Free PMC article.Clinical Trial.
- Adverse Events of Atomoxetine in a Double-Blind Placebo-Controlled Study in Children with Autism.Tumuluru RV, Corbett-Dick P, Aman MG, Smith T, Arnold LE, Pan X, Buchan-Page KA, Brown NV, Ryan MM, Hyman SL, Hellings J, Williams C, Hollway JA, Lecavalier L, Rice RR Jr, McAuliffe-Bellin S, Handen BL.Tumuluru RV, et al.J Child Adolesc Psychopharmacol. 2017 Oct;27(8):708-714. doi: 10.1089/cap.2016.0187. Epub 2017 May 16.J Child Adolesc Psychopharmacol. 2017.PMID:28509573Free PMC article.Clinical Trial.
- Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.Walker DJ, Mason O, Clemow DB, Day KA.Walker DJ, et al.Postgrad Med. 2015;127(7):686-701. doi: 10.1080/00325481.2015.1081046.Postgrad Med. 2015.PMID:26343377Review.
- A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.King S, et al.Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. doi: 10.3310/hta10230.Health Technol Assess. 2006.PMID:16796929Review.
Cited by
- Exploring the Effects of Pharmacological, Psychosocial, and Alternative/Complementary Interventions in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Meta-Regression Approach.Yang KH, Lane HY, Chang YC, Tzang RF.Yang KH, et al.Int J Neuropsychopharmacol. 2021 Oct 23;24(10):776-786. doi: 10.1093/ijnp/pyab034.Int J Neuropsychopharmacol. 2021.PMID:34086891Free PMC article.
- Risperidone for children and adolescents with autism spectrum disorder: a systematic review.Maneeton N, Maneeton B, Putthisri S, Woottiluk P, Narkpongphun A, Srisurapanont M.Maneeton N, et al.Neuropsychiatr Dis Treat. 2018 Jul 11;14:1811-1820. doi: 10.2147/NDT.S151802. eCollection 2018.Neuropsychiatr Dis Treat. 2018.PMID:30022830Free PMC article.
- The effect of autistic traits on response to and side-effects of pharmacological ADHD treatment in children with ADHD: results from a prospective clinical cohort.Lilja MM, Sandblom E, Lichtenstein P, Serlachius E, Hellner C, Bhagia J, Halldner L.Lilja MM, et al.J Neurodev Disord. 2022 Mar 6;14(1):17. doi: 10.1186/s11689-022-09424-2.J Neurodev Disord. 2022.PMID:35249540Free PMC article.
- An exploration of concomitant psychiatric disorders in children with autism spectrum disorder.Lecavalier L, McCracken CE, Aman MG, McDougle CJ, McCracken JT, Tierney E, Smith T, Johnson C, King B, Handen B, Swiezy NB, Eugene Arnold L, Bearss K, Vitiello B, Scahill L.Lecavalier L, et al.Compr Psychiatry. 2019 Jan;88:57-64. doi: 10.1016/j.comppsych.2018.10.012. Epub 2018 Nov 6.Compr Psychiatry. 2019.PMID:30504071Free PMC article.Clinical Trial.
- A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.Arnold LE, Ober N, Aman MG, Handen B, Smith T, Pan X, Hyman SL, Hollway J, Lecavalier L, Page K, Rice R Jr.Arnold LE, et al.J Child Adolesc Psychopharmacol. 2018 Jun;28(5):322-330. doi: 10.1089/cap.2017.0134. Epub 2018 Apr 25.J Child Adolesc Psychopharmacol. 2018.PMID:29694241Free PMC article.Clinical Trial.
References
- Leyfer OT, Folstein SE, Bacalman S, et al. Comorbid psychiatric disorders in children with autism: Interview development and rates of disorders. J Autism Dev Disord. 2006;36:849–861. - PubMed
- Sikora DM, Vora P, Coury DL, Rosenberg D. Attention-deficit/hyperactivity disorder symptoms, adaptive functioning, and quality of life in children with autism spectrum disorder. Pediatrics. 2012;130:S91–S97. - PubMed
- Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord. 2006;36:1101–1114. - PubMed
- Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Psychiatry. 2008;47:921–929. - PubMed
Publication types
MeSH terms
Substances
Associated data
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical